Impact of the duration of hormonal therapy following radiotherapy for localized prostate cancer

Oncology Letters

Volumn 10, Issue 1, 2015, Pages 255-259

  Okubo, Mitsuru ^a   Nakayama, Hidetugu ^a   Itonaga, Tomohiro ^a   Tajima, Yu ^a   Shiraishi, Sachika ^a   Mikami, Ryuji ^a   Sakurada, Akira ^a   Sugawara, Shinji ^a   Koizumi, Kiyoshi ^a   Tokuuye, Koichi ^a  

^a TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

Androgen Deprivation Therapy; External beam radiotherapy; Prostate Cancer

Indexed keywords

BICALUTAMIDE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER HORMONE THERAPY; CARDIOVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HIGH RISK PATIENT; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ORCHIECTOMY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RECTUM HEMORRHAGE; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT PLANNING; UROGENITAL TRACT DISEASE; VERY ELDERLY;

EID: 84929925422     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3216     Document Type: Article

References (22)

1. Watanabe H: Mass screening program for prostatic cancer in Japan. Int J Clin Oncol 6: 66-73, 2001.
2. Ogawa K, Nakamura K, Onishi H, et al; Japanese Patterns of Care Study Working Subgroup of Prostate Cancer: Radical external beam radiotherapy for prostate cancer in Japan: results of the 1999-2001 patterns of care process survey. Jpn J Clin Oncol 36: 40-45, 2006.
3. Marugame T and Mizuno S: Comparison of prostate cancer mortality in five countries: France, Italy, Japan, UK and USA from the WHO mortality database (1960-2000). Jpn J Clin Oncol 35: 690-691, 2005.
4. Bolla M, Van Tienhoven G, Warde P, et al: External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 11: 1066-1073, 2010.
5. D'Amico AV, Chen MH, Renshaw AA, Loffredo M and Kantoff PW: Androgen suppression and radiation vs. radiation alone for prostate cancer: a randomized trial. JAMA 299: 289-295, 2008.
6. Jones CU, Hunt D, McGowan DG, et al: Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 365: 107-118, 2011.
7. D'Amico AV, Denham JW, Crook J, et al: Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25: 2420-2425, 2007.
8. Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg D and Pollack A: Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 62: 397-405, 2005.
9. Bolla M, de Reijke TM, Van Tienhoven G, et al; EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group: Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360: 2516-2527, 2009.
10. Kuban DA, Thames HD, Levy LB, et al: Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 57: 915-928, 2003.
11. Sobin LH and Wittekind CH (eds): International Union Against Cancer (UICC). TNM Classification of Malignant Tumors. 6th edition. Wiley, New York, NY, 2002.
12. Roach M III, Hanks G, Thames H Jr, et al: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65: 965-974, 2006.
13. Trotti A, Colevas AD, Setser A, et al: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13: 176-181, 2003.
14. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982.
15. Epstein JI, Allsbrook WC Jr, Amin MB and Egevad LL; ISUP Grading Committee: The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 29: 1228-1242, 2005.
16. Mottet N, Peneau M, Mazeron JJ, Molinie V and Richaud P: Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol 62: 213-219, 2012.
17. Warde P, Mason M, Ding K, et al; NCIC CTG PR.3/MRC UK PR07 Investigators: Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 378: 2104-2111, 2011.
18. Widmark A, Klepp O, Solberg A, et al; Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3: Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 373: 301-308, 2009.
19. Albertsen PC, Hanley JA, Barrows GH, et al: Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 97: 1248-1253, 2005.
20. Horwitz EM, Bae K, Hanks GE, et al: Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26: 2497-2504, 2008.
21. Nanda A, Chen MH, Braccioforte MH, Moran BJ and D'Amico AV: Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 302: 866-873, 2009.
22. Lawton CA, DeSilvio M, Roach M III, et al: An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69: 646-655, 2007.